All Oncology News

Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.

Researchers are leading the nation in using powerful and precise radioactive drugs to treat people with complex cancers.

A supplemental application has been submitted to Brazil’s health regulatory agency, seeking the approval of tafasitamab for follicular lymphoma.

The first-in-class TEAD autopalmitoylation inhibitor VT3989 has received FDA orphan drug designation for the treatment of patients with mesothelioma.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

Geoffrey B. Pelz, MD, discusses the evolution of thoracic surgical oncology, along with newer minimally invasive approaches to surgery in lung cancer.

The FDA has issued a complete response letter for odronextamab in relapsed or refractory follicular lymphoma.

Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

Shailee S. Shah, MD, discusses the frequency and severity of neurologic autoimmune disorder exacerbation in patients with cancer receiving ICIs.

The first-in-class, allogeneic stem cell–loaded oncolytic virus CLD-201 was granted FDA fast track designation for the treatment of soft tissue sarcoma.

A New York cancer center appears on list for second consecutive year, based on anonymous employee surveys

Health Canada has expanded the approval of asciminib to include newly diagnosed and pretreated Ph-positive CML.

IMM2510 plus chemotherapy generated responses in the first-line treatment of advanced non–small cell lung cancer.

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Francesca Palandri, MD, PhD, discusses findings from a post hoc analysis of momelotinib-induced hemoglobin level improvements in myelofibrosis with anemia.

The Geneva HRD test was predicitive for OS and PFS benefits with olaparib plus bevacizumab in advanced ovarian cancer.

Guru P. Sonpavde, MD, discusses the role of ipilimumab/nivolumab after negative trial results in managing advanced urothelial cancer.

The FDA has granted fast track designation to ateganosine for non–small cell lung cancer.

Aditya Bardia, MD, MPH, discusses how Dato‑DXd serves as a new treatment option with a distinct safety profile in HR-positive, HER2‑negative breast cancer.

Collaboration will aim to obtain CAP/CLIA certification of organoid-based assay, followed by clinical studies in multiple indications

Onvansertib plus SOC generated responses with a tolerable safety profile in patients with previously untreated RAS-mutated metastatic colorectal cancer.

Can-Fite has reached the over 50% enrollment milestone for an ongoing phase 2a trial evaluating namodenoson in pancreatic cancer.

Joshua Richter, MD, outlines how trispecific antibodies and novel CAR T-cell therapies are shaping the 2025 myeloma landscape and improving patient access.

Janice Mehnert, MD, discusses the rationale for adding IL-6 inhibition to an ICI backbone and data with sarilumab plus ICIs in advanced melanoma.

John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.

Francesca Palandri, MD, PhD, discusses the results from a subgroup analysis of momelotinib vs ruxolitinib in myelofibrosis with anemia and low platelet counts.

BB-1701 generated responses with manageable safety in HER2-expressing breast cancer previously treated with an ADC with a topoisomerase I inhibitor.

New study takes a deep dive into how TAF1 operates to promote development of new blood cells.

Gedatolisib triplet and doublet regimens cut the risk of progression by up to 76% vs fulvestrant in HR-positive/HER2-negative advanced breast cancer.

In BRUIN CLL-314, pirtobrutinib met the primary end point of noninferior ORR vs ibrutinib in both the ITT and pretreated subsets of patients with CLL/SLL.